Correct Answer: B. Thiazides increase the tubular resorption of lithium
Lithium is filtered freely at the glomerulus and is normally reabsorbed in the proximal convoluted tube (PCT) via the same mechanism as sodium—through the epithelial sodium channel (ENaC) in competition with sodium. Thiazide diuretics cause volume depletion by inhibiting the Na-Cl cotransporter in the distal convoluted tube (DCT). This triggers compensatory mechanisms: the kidneys sense decreased intravascular volume and activate the renin-angiotensin-aldosterone system (RAAS) and increase proximal tubular sodium reabsorption to restore volume homeostasis. Because lithium reabsorption is coupled to sodium reabsorption in the PCT, increased sodium reabsorption paradoxically increases lithium reabsorption as well. This reduces urinary lithium excretion, causing lithium accumulation in plasma. Since lithium has a narrow therapeutic index (0.6–1.2 mEq/L), even modest increases in serum concentration can precipitate toxicity—manifesting as coarse tremors, confusion, ataxia, and potentially seizures. This is a classic drug–drug interaction seen in Indian clinical practice, particularly in psychiatric patients on lithium who develop hypertension. The mechanism is NOT hepatic metabolism (lithium is not metabolized) and NOT simple water loss, but rather enhanced renal reabsorption secondary to volume depletion-induced sodium retention.
Why the other options are wrong
A. Thiazide inhibits the metabolism of lithium — This is incorrect because lithium undergoes no hepatic metabolism—it is an inorganic ion that is filtered and reabsorbed unchanged by the kidneys. Thiazides do not inhibit any metabolic pathway. This option confuses lithium pharmacokinetics with drugs like phenytoin or warfarin that undergo hepatic metabolism. NBE may use this to trap students unfamiliar with lithium's unique renal-only elimination. C. Thiazides cause water loss thereby increase lithium levels — While thiazides do cause water loss, this is a superficial explanation that misses the actual mechanism. Water loss alone would dilute plasma and potentially lower lithium concentration. The true mechanism involves sodium depletion triggering proximal tubular sodium (and thus lithium) reabsorption, not osmotic concentration. This option represents a common misconception among students who confuse volume depletion with osmotic effects. D. Thiazides act as an add on drug to lithium — This is vague and incorrect. Thiazides are not 'add-on' agents to lithium therapy—they are antihypertensive drugs that happen to interact with lithium. This option lacks any pharmacological mechanism and represents a distractor for students who do not understand drug interactions. It suggests no specific interaction mechanism, which is why it fails to explain the toxicity.
High-Yield Facts
- Lithium reabsorption in PCT is coupled to sodium reabsorption via ENaC; increased sodium retention increases lithium reabsorption.
- Thiazide-induced volume depletion activates RAAS and increases proximal tubular sodium reabsorption, secondarily increasing lithium reabsorption.
- Lithium therapeutic index is 0.6–1.2 mEq/L; even 20–30% increase in serum level can cause toxicity (tremor, confusion, ataxia).
- Lithium undergoes no metabolism—it is filtered freely and reabsorbed unchanged; renal function and sodium balance are the only determinants of serum level.
- NSAIDs and ACE inhibitors also increase lithium levels by reducing renal perfusion and GFR; thiazides are a major culprit in Indian psychiatric practice.
- Monitoring strategy: check serum lithium 5–7 days after starting thiazide; reduce lithium dose by 25–50% if thiazide is unavoidable; prefer calcium channel blockers or beta-blockers for hypertension in lithium patients.
Mnemonics
LITHIUM LOSS DRUGS (Increase Lithium Levels) Thiazides, NSAIDs, ACE-I, Dehydration → TNAD. All cause volume/sodium depletion → increased proximal tubular lithium reabsorption → toxicity. Lithium Reabsorption = Sodium Reabsorption Lithium competes with sodium in the PCT. When sodium is retained (due to volume depletion from thiazides), lithium is retained too. Less sodium loss = Less lithium loss = Lithium toxicity.
NBE Trap
NBE pairs "water loss" with "increased lithium levels" to trap students who confuse volume depletion with osmotic concentration. The correct mechanism is sodium reabsorption-coupled lithium reabsorption, not simple dehydration. Students who think "less water = more concentrated lithium" will choose option C and miss the renal physiology.
Clinical Pearl
In Indian psychiatric practice, lithium is still a first-line mood stabilizer for bipolar disorder. When an Indian patient on lithium develops hypertension, thiazides are often the first-line choice—but this combination is a major drug interaction trap. Always counsel patients to maintain sodium and fluid intake, monitor serum lithium every 5–7 days after starting a thiazide, and consider alternative antihypertensives (amlodipine, labetalol) in lithium-treated patients.
_Reference: KD Tripathi Pharmacology Ch. 12 (Diuretics & Lithium); Harrison Ch. 297 (Renal Physiology); Robbins Ch. 7 (Acute Kidney Injury & Drug-Induced Renal Disease)_